Merck Stands On EDGE: Arcoxia Data Presented On Eve Of FDA Action Date

An increased incidence of hypertension observed in the 12-month Arcoxia EDGE trial could pose an obstacle to approval of Merck's Vioxx follow-on product as FDA's action deadline draws near